Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas

• Authors: HULSTAERT E.; MORLION A.; COBOS F.A.; VERNIERS K.; NUYTENS J.; VANDEN EYNDE E.; YIGIT N.; ANCKAERT J.; GEERTS A.; HINDRYCKX P.; JACQUES P.; BRUSSELLE G.; BRACKE K.R.; MAES T.; MALFAIT T.; DERVEAUX T.; NINCLAUS V.; VAN CAUWENBERGH C.; ROELENS K.; ROETS E.; HEMELSOET D.; TILLEMAN K.; BROCHEZ L.; KUERSTEN S.; SIMON L.M.; KARG S.; KAUTZKY-WILLERS A.; LEUTNER M.; NOHAMMER C.; SLABÝ Ondřej; PRINS R.W.; KOSTER J.; LEFEVER S.; SCHROTH G.P.; VANDESOMPELE J.; MESTDAGH P.
• Year of publication: 2020
• Type: Article in Periodical
• Magazine / Source: Cell Reports
• MU Faculty or unit: Central European Institute of Technology
• Web: https://www.sciencedirect.com/science/article/pii/S2211124720315412?via%3Dihub
• Doi: http://dx.doi.org/10.1016/j.celrep.2020.108552
• Keywords: MESSENGER-RNA; CIRCULAR RNA; EXPRESSION; LANDSCAPE; MICRORNA; BIOMARKERS
• Description: Extracellular RNAs present in biofluids have emerged as potential biomarkers for disease. Where most studies focus on blood-derived fluids, other biofluids may be more informative. We present an atlas of messenger, circular, and small RNA transcriptomes of a comprehensive collection of 20 human biofluids. By means of synthetic spike-in controls, we compare RNA content across biofluids, revealing a 10,000-fold difference in concentration. The circular RNA fraction is increased in most biofluids compared to tissues. Each biofluid transcriptome is enriched for RNA molecules derived from specific tissues and cell types. Our atlas enables an informed selection of the most relevant biofluid to monitor particular diseases. To verify the biomarker potential in these biofluids, four validation cohorts representing a broad spectrum of diseases were profiled, revealing numerous differential RNAs between case and control subjects. Spike-normalized data are publicly available in the R2 web portal for further exploration.

Related projects

• Usage of urinary/tissue microRNAs to increase PSA specificity and distinguish between indolent and aggressive forms of prostate cancer
• Extension of established prognostic scores in brain metastases by microRNA profiling to tailor the post-operative personalized care